-+ 0.00%
-+ 0.00%
-+ 0.00%

MONTE ROSA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MODEFIRE-1, A PHASE 2 STUDY OF MRT-2359 IN COMBINATION WITH APALUTAMIDE IN PATIENTS WITH AR MUTATION-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Reuters·08/24/2026 11:00:01

Please log in to view news